Patent ID: 7098201

Claim:
A method for treating AIDS related to HIV-1, HIV-2, SIV, and FIV infections, which comprises administering to a patient in need thereof a compound of the formula (I): wherein X is hydroxy, protected hydroxy or optionally substituted amino; Y is —COOR A , —CONR B R C , optionally substituted aryl or optionally substituted heteroaryl, wherein said R A is hydrogen or ester residue, said R B and R C each is independently hydrogen or amide residue, and said aryl is a monocyclic aromatic hydrocarbon group or a polycyclic aromatic hydrocarbon group; A 1 is heteroaryl is selected from the group consisting of (1) a 5- to 8-membered heteroaromatic group containing 1 to 4 oxygen atom, sulfur atom and/or nitrogen atom in the ring and (2) a fused heteroaryl which is a heteroaromatic group wherein a 5- to 8-membered aromatic ring containing 1 to 4 oxygen atom, sulfur atom and/or nitrogen atom in the ring is fused with 1 to 4 5- to 8-membered aromatic carbon ring or other 5- to 8-membered heteroaromatic ring optionally substituted with -(Z 4 -R 2 )p and/or -Z 1 -Z 2 -Z 3 -R 1 , Z 1 and Z 3 each is independently a bond, lower alkylene or lower alkenylene; Z 2 and Z 4 each is independently a bond, lower alkylene, lower alkenylene, —CH(OH)—, —S—, —SO—, —SO 2 —, —SO 2 NR 21 , —NR 21 SO 2 —, —O—, —NR 21 —, —NR 21 CO—, —CONR 21 —, —C(═O)—O—, —O—C(═O)— or —CO—; R 21 is hydrogen, lower alkyl or lower alkenyl; R 1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle, wherein said aryl is a monocyclic aromatic hydrocarbon group or a polycyclic aromatic hydrocarbon group; R 2 is optionally substituted lower alkyl, optionally substituted lower alkyloxy, optionally substituted lower alkyloxycarbonyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted aryloxycarbonyl, carboxy, optionally substituted cycloalkyl, hydroxy, mercapto, optionally substituted amino, nitro or halolgen, wherein said aryl is a monocyclic aromatic hydrocarbon group or a polycyclic aromatic hydrocarbon group; and p is 0 or 1; or a tautomer, a prodrug, a pharmaceutically acceptable salt or a hydrate thereof, provided that a compound wherein Y and/or A 1 is optionally substituted indol-3-yl is excluded.